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Summary This study was designed to describe the course of epilepsy (in terms of
seizure frequency) and to assess the variables (antiepileptic therapy regimens and
others) correlated to improvement. Seizure frequency (categories: seizure free, more
than one seizure/year, monthly seizures, weekly seizures and daily seizures) and
antiepileptic medication were retrospectively compared between 1992 and 2002 in a
large cohort of 550 inpatients with chronic epilepsy and different degrees of intel-
lectual disability or multiple handicaps.
Results: Seizure frequency decreased significantly ( p < 0.001). 218 of the 394
patients (55.3%) not seizure free in 1992 improved (changed into a better frequency
category). The improvement rate was marginally higher in patients who had under-
gone amedication change ( p = 0.08). A high seizure frequency in 1992 ( p = 0.016) and
older age ( p = 0.006), but not epilepsy syndrome or degree of intellectual disability,
were predictors for improvement (stepwise logistic regression analysis).
56.4% of the improved patients were on combinations of two AEDs (17.4%,
monotherapy; 20.2%, triple therapy). The most frequent therapy regimens in the
improved patients were lamotrigine/valproate (48 patients), carbamazepine/phe-
nobarbital (21) and carbamazepine only (19). Lamotrigine/valproate was effective in
all kinds of epileptic syndromes. Most patients on lamotrigine had serum concentra-
tions above 10 mg/ml, approximately one half had dosages above 200 mg/day. The
rate of seizure freedom increased from 28.4 to 37.6%. The 84% of the patients seizure
free in 1992 remained seizure free. Predictors for seizure freedom in 2002 were higher
age (stepwise logistic regression, p < 0.0005) and seizure freedom in 1992
( p < 0.0005).
Conclusions: Substantial improvement can be achieved even in intellectually dis-
abled patients with chronic epilepsy. Although the rate of seizure freedom is reduced* Corresponding author. Tel.: +49 521 1442829; fax: +49 521 1444736.
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in comparison with a non-ID population, once seizure freedom has been achieved
it is most likely to continue. For a majority of this patient population, monotherapy
may not be sufficient. Lamotrigine/valproate appears to be a major therapeutic
innovation.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Epilepsies in the context of intellectual disabilitya
(ID) are often characterised by a high seizure fre-
quency and multiple seizure types.1 Although it is
well-known that they are difficult to treat or resis-
tant to treatment in many cases more detailed
information about the long-term course of epilepsy
is scarce. In one of the rare longitudinal studies the
rate of seizure free patients decreased from 71 to
58% over a 12 years period.2 There is also a lack of
information on the long-term impact of the new
antiepileptic drugs (AEDs) in ID patients. While a
number of studies have focussed on the responder
rates and tolerability of single drugs, it is virtually
unknown to what extent the ID population in general
has benefited from innovative therapies.
The intention of this study was to assess the
course of epilepsy (in terms of seizure frequency)
over a period of 10 years as well as the impact of
different antiepileptic drug regimens (classic and
new AEDs) and other variables on seizure frequency
in intellectually disabled patients with longstanding
epilepsy.
During such a long period, antiepileptic therapy
could have remained stable or have undergone
numerous changes in different patients. There is
no standardised way to follow such a diversity of
therapies in all detail in a large number of patients.
We therefore chose for the approach of two ‘‘snap-
shots’’, a comparison of the seizure frequencies and
therapeutic regimens in the years 1992 and 2002.Methods
We investigated retrospectively the inpatients of
the residential department of the Bethel epilepsy
centre which provides long-term care for patients
with epilepsy and different degrees of intellectual
and/or physical disabilities. While some of the older
resident patients who were admitted decades ago
have less severe epilepsy, the majority of the more
recently admitted, mostly younger patients suffer
from difficult-to-treat epilepsies. Our investigationa The terms intellectual disability and learning disability are
used synonymously in this text.was carried out in the whole main body of the
organisation which is located in the city of Bielefeld.
Only two residences which care for a different
clientele were excluded. All residents in permanent
residential care since 1992 or longer with a diagnosis
of epilepsy were included. Study participants
therefore have long-standing epilepsy with differ-
ent degrees of severity as well as the whole spectre
of intellectual and physical impairments (from
borderline intelligenceb to profoundly multi-handi-
capped).
Long-term antiepileptic treatment has been car-
ried out by a team of neurologists and psychiatrists
with special interest and experience in the diagnosis
and treatment of epilepsy. Therapy has reflected
normal clinical practice with no formal protocol
followed but adhering to acknowledged principles:
to achieve seizure freedom whenever possible; if
this was not possible, to reach a maximum reduction
in seizure frequency and severity; to strive for the
patients’ best possible quality of life through a
balance between seizure control and side effects;
to limit the number of AEDs prescribed in the indi-
vidual patient to the minimum needed; to respect
the expressed wishes of the patients or their
legal representatives. Patients were seen and drug
therapy was reviewed in regular intervals (approxi-
mately every 2 weeks to every 3 months) according
to clinical needs.
In 2003, a data sheet was filled in by the authors
on all patients included. Data extracted from the
individual case histories and from the current case
documentation included seizure frequency and anti-
epileptic medication in 1992 and 2002, the diagnosis
of epileptic syndrome (based on seizure descriptions
and EEG findings, according to the International
League Against Epilepsy classification3), and degree
of learning disability. Seizure frequency was subdi-
vided into the following categories: completely sei-
zure free; nearly seizure free (compatible with one
uncomplicated seizure during the whole year or with
one or two seizures due to acute disease or forgot-
ten medication or with isolated auras); more than
one seizure/year; more than one seizure/month;b Borderline intelligence is usually defined by an IQ from 70—85.
For the purpose of this study, patients with relevant learning
difficulty due to severe neuropsychological deficits like memory
disorder, etc. were also included in this category.
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Table 1 Patient characteristics
Learning disability N Epilepsy syndrome N Age group (in 2002) N
Mild 144 Sympt. focal 246 18—29 37
Moderate 201 Focal + gen.a 128 30—39 113
Severe 125 Sympt. gen. 59 40—49 110
Profound 25 Sympt. multifocal 37 50—59 102
Borderline * 51 LGS 42 60—69 125
Unknown 4 Idiopathic gen. 16 70—79 52
Unclassifiable 22 >80 11
Sympt. focal: symptomatic or cryptogenic (probably symptomatic) focal epilepsy; focal + gen.: epilepsy with focal and generalised
features; sympt. gen.: symptomatic/cryptogenic generalised epilepsy; sympt. multifocal: symptomatic/cryptogenic multifocal
epilepsy; LGS: Lennox Gastaut syndrome; idiopathic gen.: idiopathic generalised epilepsy.
a International League Against Epilepsy subclass 3.1: ‘epilepsies and syndromes undetermined whether they are focal or general-
ised–—with both generalised and focal seizures’.3
* Borderline intelligence.more than one seizure/week; more than one sei-
zure/day. If antiepileptic medication had not been
stable throughout the whole year 1992 or 2002,
certain rules were applied to choose the key date
within the year (longest period of time with stable
medication; day when a [trough] serum level was
determined; if more than one trough serum level
had been determined: the latest).
Changes in seizure frequency were evaluated as
follows: patients who changed into a better category
from 1992 to 2002 will be referred to as ‘‘improved’’,
those who changed into the next better category but
one (ormore)will be called ‘‘strongly improved’’. For
example, if apatientwithweekly seizures in1992had
more than one seizure/month in 2002, he was
‘‘improved’’, if he had only more than one seizure/
year in 2002, he was ‘‘strongly improved’’. Patients
who remained in the same category were
‘‘unchanged’’, patients in a category with higher
seizure frequency ‘‘worsened’’. Nearly seizure free
and completely seizure free were evaluated as one
common category.With thismethod, only substantial
changes of seizure frequency were covered.
Out of 867 residents, 580 met the inclusion cri-
teria. Twenty-five had to be excluded, 5 because the
1992 files were completely lacking, 20 for different
reasons (insufficient data; epilepsy surgery carried
out between 1992 and 2002, or because frequent
additional psychogenic non-epileptic paroxysmal
events made it impossible to determine the fre-
quency of epileptic seizures). Five patients who
developed epilepsy after 1992 were not included
either. The remaining 550 patients formed the study
cohort.Figure 1 Seizure frequencies in 1992 and 2002.Results
For the characteristics of the 550 patients (male,
299; female, 251) see Table 1.There was a clear decrease in seizure frequen-
cies from 1992 to 2002 (Wilcoxon test, p < 0.001).
The number of patients with frequent (daily or
weekly) seizures decreased considerably (Fig. 1).
The number of seizure free patients increased
from 156 (121 completely, 35 nearly seizure free)
to 207 (159 completely, 48 nearly seizure free).
218 patients had an improvement in seizure fre-
quency. 275 patients remained unchanged while 57
worsened.
Further development of patients who
were seizure free in 1992
131 out of the 156 patients (84.0%) seizure free in
1992 remained seizure free (Table 2). In 53 (40.5%)
of these, antiepileptic therapy remained
unchanged. In 52 (39.7%) of the 131 patients, some
type of medication reduction had been carried out.
In 21 cases, the dosage of one ormore AEDs had been
reduced. In 28 patients, one or more AEDs had been
removed out of the original 1992 regimen (in 25
patients 1 AED, in 2 patients two AEDs, and in one
patient 3 AEDs). AEDs most often involved in this
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Table 2 Development of seizure frequencies
Fields with a margin: number of unchanged patients; fields right/above of those with margin: number of worsened patients; grey
background: number of improved patients (darker grey: strongly improved).were PBc (13 cases, +2 cases PRM), CBZ (9), and PHT
(4). The most frequent change was from CBZ/PB to
CBZ alone. In three patients, medication had been
completely discontinued. In 23 of the 131 patients
(17.6%), therapy had been altered (apart from the
reductions already mentioned): 10 patients had a
different regimen, 13 a substantial change in dosage
or serum concentration.
25 (16.0%) of the formerly seizure free patients
had again seizures in 2002, 15 patients had >1
seizure/year, 9 had >1 seizure/month, and one
patient had >1 seizure/week (Table 2).
Further development of patients who had
seizures in 1992
218 of the 394 patients (55.3%) not seizure free in
1992 were improved in 2002. Fifty-nine (15.0%) of
them were strongly improved. Table 2 gives details
on the number of patients who changed from one
seizure frequency category to another.
The improvement rate was marginally higher in
patients who had undergone a medication change
(197 improved of 347 whose medication was chan-
ged; 56.8%) than in those whose medication was
unchanged (21 of 47 or 44.7% improved; p = 0.08,
Fisher’s exact test, one-sided).
Predictors for improvement
We assumed other factors besides AED changes
could have influenced changes in seizure frequency.c Abbreviations of AEDs: CBZ: carbamazepine; GBP: gabapen-
tin; LEV: levetiracetam; LTG: lamotrigine; OCBZ: oxcarbazepine;
PB: phenobarbital; PHT: phenytoin; PRM: primidone; TPM: topir-
amate; VGB: vigabatrin; VPA: valproate.The improvement rates in different degrees of ID,
in different epileptic syndromes, in different age
groups and according to seizure frequency in 1992
are shown in Table 3.
Univariate analysis revealed that high improve-
ment rates were correlated with a high seizure
frequency in 1992 (p = 0.017, test of trend, two-
sided) and weakly correlated with higher age
(p = 0.092, test of trend, two-sided). There was
also a correlation between high seizure frequency
in 1992 and a medication change ( p = 0.001, test of
trend, two-sided). There was neither a significant
correlation between epilepsy syndrome and
improvement rate nor between degree of intellec-
tual impairment and improvement rate (Table 3).
Stepwise logistic regression analysis including
epilepsy syndrome, age group, and seizure fre-
quency in 1992, found only seizure frequency
(OR = 1.474,d CI 95% 1.16—1.87, p = 0.016) and older
age (OR = 1.24, CI 95% 1.06—1.44, p = 0.006) to be
predictors for improvement.
Antiepileptic therapy of improved patients
38 of the improved patients (17.4%) were on mono-
therapy (CBZ: 19; VPA: 8; PB: 6; PHT: 3; LTG: 2).
More than a half (123; 56.4%) of the improved
patients was on a combination of two AEDs. LTG/VPA
(48; 17 of them strongly improved) and CBZ/PB (21;
5 of them strongly improved) were by far the most
frequent out of a total of 24 different duotherapies
(OCBZ/VPA: 9; CBZ/VPA: 7; PB/VPA: 6; PB/PHT: 5;
all others: <5).
44 improved patients (20.2%) were on a combi-
nation of three AEDs (LTG/PB/VPA: 7; CBZ/LTG/d OR: odds ratio; CI: confidence interval.
Long-term course of epilepsy in intellectually disabled patients 39
Table 3 Improvement rates according to different variables (patients not seizure free in 1992, N = 394)
Learning
disabilty
Improvement
rate (%)
Epilepsy
syndrome
Improvement
rate (%)
Age group
(in 2002)
Improvement
rate (%)
Sz frequency
in 1992
Improvement
rate
Mild 59.0 Sympt. focal 55.6 18—29 47.1 Sz free 0
Moderate 57.3 Focal + gen. 53.3 30—039 52.6 >1/year 44 (50.0%)
Severe 50.0 Sympt. gen. 78.3 40—49 55.2 >1/month 54 (49.5%)
Profound 52.4 Sympt. multifocal 50.0 50—59 52.9 >1/week 93 (58.1%)
Borderlinea 51.7 LGS 50.0 60—69 60.2 >1/day 27 (73.0%)
Unknown Idiopathic gen. 71.4 70—79 68.2
Unclassifiable 40.0 >80 66.7
N.s. N.s. p = 0.092b p = 0.017b
N.s.: not significant; sz: seizure; for abbreviations of epileptic syndromes see Table 1.
a Borderline intelligence.
b Test of trend, two-sided.VPA: 3; all others: <3). Altogether, there were 29
different triple combinations. Thirteen improved
patients (6.0%) were on 13 different combinations
of 4 AEDs.
In total, there was a diversity of 71 different
therapeutic regimens in the improved patients, but
only a few of them are salient (Fig. 2).
Fig. 3 shows the therapeutic regimenswhich led to
improvement in the different epilepsy syndromes.
Fig. 4 gives details of LTG/VPA, the most impor-
tant therapeutic regimen. The spectrum of LTGFigure 2 Therapy regimens of improved patients. Dark
grey portion of the columns: strongly improved patients.
Figure 3 Epilepsy syndromes/successful therapeutic
regimens. Abbreviations: see Table 1.dosages and serum concentrations used was broad
with a majority of serum concentrations above 10
and also above 15 mg/ml. In detail, the daily doses
and serum concentrations (mean value  standard
deviation) in the 48 improved patients on LTG/VPA
were: LTG 242.8  99.2 mg; 14.2  3.5 mg/ml; VPA
1796.9  769.5 mg; 82.8  24.5 mg/ml.
Thedaily doses and serumconcentrations in the 21
improved patients on CBZ/PB were: CBZ 1378.6
 421.8 mg; 8.1  2.5 mg/ml; PB 118.8  39.7 mg;
21.7  7.6 mg/ml.
The corresponding values in the 19 improved
patients on CBZ monotherapy were: 1471.1 
517.0 mg; 10.8  2.2 mg/ml.Figure 4 Improvement on LTG/VPA (48 cases). Coeffi-
cients of correlation: r = 0.53 (LTG); r = 0.54 (VPA).
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A stepwise logistic regression analysis revealed that
predictors for seizure freedom in 2002 were higher
age (OR = 1.42, CI 95% 1.21—1.66, p < 0.0005) and
seizure freedom in 1992 (OR = 16.4, CI 95% 9.8—
27.3, p < 0.0005). Seizure freedom in 2002 was
negatively correlated with change of medication
(OR = 0.49, CI 95% 0.27—0.86, p = 0.014). Seventy-
six patients who still had had seizures in 1992 were
seizure free in 2002 (19.3%).Discussion
A study like this has obvious limitations, mainly due
to its retrospective character which, among others,
did not allow including those patients who died or
left the institution between 1992 and 2002. It is
evident that results obtained in a selected popula-
tion cannot plainly be generalised about an average
epilepsy population. On the other hand, strengths
are the quality of seizure documentation (seizure
records accurately kept on every resident patient
for decades) which appeared to be good in an
organisation with a long tradition of epilepsy care,
and the low rate of exclusions due to incomplete
data. Another strong point is the large number of
patients followed over a prolonged period of time.
It is well-known that the therapy prognosis in
terms of seizure freedom is worse in ID patients
than in a non-handicapped epilepsy population. For
example, the proportions of seizure free patients in
similar samples were 44.1,4 275 and 43%,6 as
opposed to an expected approx. three quarters in
an average epilepsy population. The rate of seizure
freedom in our study (28.4% in 1992, 37.6% in 2002)
is within this range. However, the number of new
seizure free patients (76, or 19.3%) is surprisingly
high in this selected and predominantly difficult-to-
treat sample. And what is more, the rate of 55.3%
improved patients indicates that, even if complete
seizure control may not be a realistic goal for the
majority of these patients, substantial improvement
in seizure frequency can be achieved through con-
tinual therapeutic trials. As Tables 2 and 3 have
shown, especially a remarkable part of those with
frequent seizures improved. In the epidemiological
study by Forsgren4 only a minority of patients had
frequent seizures (32.1% yearly seizures, 12.6%
monthly, 11.3% weekly, 2.7% daily seizures). This
is in sharp contrast to the distribution of seizure
frequencies in our study (mainly in 1992) which
reflects the selected clientele of an epilepsy centre.
Our improvement rate of 55.3% is similar to that
of a comparable study by Scheepers et al.7 Theseauthors achieved an improvement rate of 57% over a
period of 2 years. However, their criterion (a 50%
reduction in seizure frequency) was less strict than
ours. In their study, most of the improvements were
due to the introduction of LEVand LTG while the use
of classic AEDs decreased.
Opposite to these results, in the abovementioned
study by Branford et al.2 the rate of seizure freedom
decreased from 1985 until 1997. At the same time,
the use of polypharmacy increased. New AEDs (GBP,
LTG and also VGB) were beginning to be used. An
explanation for the deterioration given by the
authors was a change in the care setting of many
of these patients which may have led to a loss of
specialist treatment. The lack of a correlation
between seizure outcome and degree of ID is in
accord with the results by Sillanpa¨a¨8 and Kelly.6
It would be a simplification to attribute the
improvements seen in this population exclusively
to AED changes and to ignore other variables such as
the spontaneous course of the disease, the increase
in age of our study population, additional psycho-
social and other external factors. It is therefore no
surprise that the correlation between medication
change and improvement was only marginally sig-
nificant. Statistical analysis revealed a high seizure
frequency and also older age as predictors of
improvement. The higher improvement rates in
patients with frequent seizures might be inter-
preted, in statistical terms, as a regression to the
mean which should be taken into account as a
confounding factor. For older age it remains unde-
termined if the natural course of the disease was
the decisive factor, or if a selection bias was con-
founding (younger patients admitted to the organi-
sation may have more severe epilepsy than older
patients).
Even though the rate of seizure freedom is gen-
erally lower in ID patients, our results indicate that
once a patient is seizure free the prognosis as for
constant seizure freedom is very good. This is in
contrast to the findings by Sillanpa¨a¨8 who reported a
higher relapse risk after 5 years of seizure freedom
for patients with versus without learning disability.
As ID and also neurological deficit are known risk
factors for seizure relapse after terminating ther-
apy9 our approach towards seizure free patients has
been cautious. Medication has frequently been sim-
plified or reduced but only rarely completely dis-
continued in seizure free patients.
Monotherapy was still the domain of classic AEDs
(mainly CBZ and VPA) in our study. We feel this was
mainly a consequence of regulatory policies (intro-
duction of new AEDs only for add on treatment,
delayed approval for monotherapy). While mono-
therapy is considered the treatment of choice by
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AEDs) count for a majority of the improvements in
our study. One might conclude that in chronic epi-
lepsy — as opposed to uncomplicated or newly
diagnosed epilepsy — monotherapy is not sufficient
for many patients. Other authors have pointed out
that combination therapy does not necessarily lead
to an increase in adverse effects.10
LTG/VPA has been the therapy regimen most
frequently used in improved and also in strongly
improved patients (Fig. 2). This is in accord with
the opinion of some experts who believe the com-
bination of LTG and VPA to be the quintessential
example of rational combination therapy.11 Our
clinical experience suggests that this combination
is also well tolerated by intellectually disabled
patients. Our data on LTG indicate that the manu-
facturer’s recommended daily dosage (100—
200 mg/day in combination with VPA) may be much
too low (Fig. 4), at least in difficult-to-treat
patients. They confirm the findings by Hirsch
et al.12 who also reported increasing efficacy of
LTG in serum levels up to >20 mg/ml.
As no systematic comparison has been made
between LTG/VPA and LTG or VPA alone, only cau-
tious conclusions should be drawn from our results.
But interestingly, in a similarly designed study13 the
combination LTG/VPA was also most successful, a
fact which coincides with our findings. While most
recommendations on how to combine AEDs are the-
ory-based, e.g. to combine drugs of different modes
of action, these results provide clinical support to
the view that LTG/VPA is a major innovation of the
last decade.
The therapy regimen most successful but one has
been CBZ/PB (Fig. 2) suggesting that this combina-
tion of classic AEDs remains an effective therapeutic
option. This combination had been used much more
frequently in our organisation before the era of the
new AEDs. Another successful duotherapy was
OCBZ/VPA which may have replaced in part the
traditional combination CBZ/VPA due to its meta-
bolic advantages.
Our findings suggest that there is no major varia-
tion in improvement rates between the different
epileptic syndromes (Table 3). Due to the uneven
syndrome distribution it is also difficult to recognise
differences in the improvement rates on the various
therapy regimens with respect to epilepsy syn-
dromes (Fig. 3). LTG/VPA apparently is effective
in all major forms of epilepsy. Only for CBZ (mainly
alone but also in combination with PB) one might
detect a lack of effect in LGS and symptomatic
generalised epilepsy as compared to focal epilepsy.
This corresponds with the well-known indication of
CBZ which is mainly in focal epilepsy.One might be surprised by the fact that after a
decade during which more than half a dozen of new
AEDs were introduced nearly as many improvements
were achieved by optimisation of therapy with
classic AEDs as by the use of new AEDs. The limited
role of the new AEDsmay be a question of time in the
case of LEV which was introduced only in autumn of
2000, quite shortly before this investigation. For
others it might be due to the experience of ineffi-
cacy (GBP)14 or increased toxicity (TPM)15 made in
this population. The great proportion of classic AEDs
in the improved patients could also be taken as a
reminder not to neglect the classic AEDs despite the
wave of new drugs.
Different studies have stressed the importance
of seizure control for the patients’ quality of life.16
Personal experience with the course of treatment
of many of the patients included, although not
systematically documented, and also carers’ feed-
back in a number of cases makes us believe that
the reported improvements in seizure activity
led to parallel improvements of quality of life in
many of our patients. A formal assessment of this
topic, unfortunately, was beyond the scope of this
study.
We believe our knowledge on useful therapy regi-
mens is only at the beginning, especially in the
difficult-to-treat epilepsies of intellectually handi-
capped patients and further investigation in this
field is needed.References
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